CA2390161A1 - Methods for identifying and using amyloid-inhibitory compounds - Google Patents

Methods for identifying and using amyloid-inhibitory compounds Download PDF

Info

Publication number
CA2390161A1
CA2390161A1 CA002390161A CA2390161A CA2390161A1 CA 2390161 A1 CA2390161 A1 CA 2390161A1 CA 002390161 A CA002390161 A CA 002390161A CA 2390161 A CA2390161 A CA 2390161A CA 2390161 A1 CA2390161 A1 CA 2390161A1
Authority
CA
Canada
Prior art keywords
beta
animal
level
estrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390161A
Other languages
English (en)
French (fr)
Inventor
Suzana Petanceska
Sam Gandy
Donald E. Frail
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATHAN S KLINE RESEARCH INSTITUTE
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2390161A1 publication Critical patent/CA2390161A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
CA002390161A 1999-11-05 2000-11-03 Methods for identifying and using amyloid-inhibitory compounds Abandoned CA2390161A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16381999P 1999-11-05 1999-11-05
US60/163,819 1999-11-05
PCT/US2000/030310 WO2001035106A2 (en) 1999-11-05 2000-11-03 Methods for identifying and using amyloid-inhibitory compounds

Publications (1)

Publication Number Publication Date
CA2390161A1 true CA2390161A1 (en) 2001-05-17

Family

ID=22591720

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390161A Abandoned CA2390161A1 (en) 1999-11-05 2000-11-03 Methods for identifying and using amyloid-inhibitory compounds

Country Status (10)

Country Link
US (1) US20080085244A1 (https=)
EP (1) EP1272853A2 (https=)
JP (2) JP2003522737A (https=)
AR (1) AR027878A1 (https=)
AU (2) AU2005200176B2 (https=)
CA (1) CA2390161A1 (https=)
MX (1) MXPA02004480A (https=)
NZ (3) NZ518780A (https=)
TW (3) TW200834074A (https=)
WO (1) WO2001035106A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20020173499A1 (en) * 2001-03-16 2002-11-21 Wyeth Estrogen replacement therapy
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US8658627B2 (en) 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2698167A3 (en) * 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JP3552272B2 (ja) * 1994-05-27 2004-08-11 帝国臓器製薬株式会社 免疫化学的簡易アッセイ方法および装置
WO1997046664A1 (en) * 1996-06-06 1997-12-11 University Of Washington Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
JPH1090261A (ja) * 1996-08-23 1998-04-10 Fuotoreru Patrick 性ステロイドホルモン測定用プレート、これを用いた測定キット及び測定法
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
AU7260398A (en) * 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Also Published As

Publication number Publication date
EP1272853A2 (en) 2003-01-08
AU2005200176A1 (en) 2005-02-10
TWI265026B (en) 2006-11-01
JP2008058329A (ja) 2008-03-13
NZ518780A (en) 2006-02-24
NZ543850A (en) 2009-03-31
TWI302099B (en) 2008-10-21
TW200621221A (en) 2006-07-01
US20080085244A1 (en) 2008-04-10
AU1459201A (en) 2001-06-06
AR027878A1 (es) 2003-04-16
MXPA02004480A (es) 2004-09-10
AU2005200176B2 (en) 2007-10-25
NZ536461A (en) 2005-02-25
AU779781B2 (en) 2005-02-10
WO2001035106A2 (en) 2001-05-17
JP2003522737A (ja) 2003-07-29
TW200834074A (en) 2008-08-16
WO2001035106A3 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
US20080085244A1 (en) Methods for identifying and using amyloid-inhibitory compounds
Ghosh et al. Alzheimer’s disease-related dysregulation of mRNA translation causes key pathological features with ageing
Montine et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype
US7888066B2 (en) Methods for identifying substances for the treatment of Alzheimer's disease
Ramakrishnan et al. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies
Tang et al. Estrogen increases brain expression of the mRNA encoding transthyretin, an amyloid β scavenger protein
Cuadrado-Tejedor et al. Age-related mitochondrial alterations without neuronal loss in the hippocampus of a transgenic model of Alzheimer's disease
Garza-Contreras et al. Presence of androgen receptor variant in neuronal lipid rafts
Leone et al. Increased pain and inflammatory sensitivity in growth hormone-releasing hormone (GHRH) knockout mice
Sarsoza et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain
Gao et al. Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy
US20120021924A1 (en) Detection and modulation of cytochrome c acetylation
Sharoar et al. Dynactin 6 deficiency enhances aging-associated dystrophic neurite formation in mouse brains
US8673851B2 (en) Synapse-specific proteins in glomeruli
AU2008200349A1 (en) Methods for identifying and using amyloid-inhibitory compounds
US20180085423A1 (en) Methods for treating and diagnosing eating disorders
Vettorazzi et al. Changes in male rat urinary protein profile during puberty: a pilot study
Bhagavan et al. Restoration of TEA-induced calcium responses in fibroblasts from Alzheimer's disease patients by a PKC activator
JP2007082546A (ja) 毒性作用のマーカーとしてのｆａｂｐ４
Timmers et al. Neuropeptide content in pancreas and pituitary of obese and diabetes mutant mice: strain and sex differences
Barron et al. Ovariectomy and 17β-estradiol replacement do not alter β-amyloid levels in sheep brain
NO338179B1 (no) Anvendelse av prionkonverteringsmodulerende midler
JP2010101880A (ja) マイクロドメイン病のバイオマーカー
Prince et al. Developmental analysis and influence of genetic background on the lhx3 w227ter mouse model of combined pituitary hormone deficiency disease
Cervera-Pierot et al. Hippocampal and Parahippocampal Somatostatin 28 and Neuropeptide Y Containing Neurons in Alzheimer's Disease (Part 2 of 2)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued